<DOC>
	<DOCNO>NCT00724022</DOCNO>
	<brief_summary>Current practice immune suppressive standard therapy renal transplantation non-risk patient triple therapy consist steroid , calcineurin inhibitor MMF . The aim clinical trial combine reduction CNI use tacrolimus concept use steroid order establish immunosuppressive regimen immunologically non-risk patient efficient cause side effect possible .</brief_summary>
	<brief_title>Phase IV Study Evaluate Calcineurin Inhibitor Reduced , Steroid Free Immunosuppression After Renal Transplantation</brief_title>
	<detailed_description>In triple arm , prospectively randomize multi centre phase IV study 200 patient per study arm investigate 12 month . Based result Symphony study low dose tacrolimus study arm modify improve efficacy ( prevention BPAR , best possible renal function ) safety ( adverse event profile regard infection , cardiovascular risk factor , malignant tumour ) immunosuppression . For , CNI reduce addition rate steroid free patient 1 week maximize achieve long last improve post surgical cardiovascular risk profile ( particular concern de novo induction diabetes mellitus adverse event cause steroid ) . Safety increase without loss efficacy immunosuppression ( measure rejection rate allograft loss rate ) compare immune suppressive therapy comprise steroid . Therefore , follow successful study arm Symphony study , immunosuppression first three study arm comprise steroid combination Advagraf CellCept addition two dose induction therapy Simulect ( group A ) . The regimen second study arm similar discontinues steroid day seven transplantation ( group B ) . Therapy group three similar group B Simulect replace T-cell deplete polyclonal antibody ( Thymoglobulin ) ( group C ) .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Post mortal kidney donation live donation Primary secondary renal transplantation , unless graft lose due severe rejection within first year PRA level ≤ 20 % . Recipient ≥ 18 75 year age AB0compatible Negative crosshatch Patients sign informed consent form Women childbearing age must agree efficient contraception Third multiple transplantation Transplantation per `` nonheart beating '' donor HLAidentical living donation Incompatibility study medication ( allergy , intolerance , hypersensitivity ) Patients exist malignant underlying disease tumour anamnesis &lt; 5 year . Exception : basaloma squamous cell carcinoma skin successful therapy Female patient use safe method contraception Patients clinically significant , uncontrolled infectious disease ( incl . HIV ) and/or severe diarrhoea , emesis , active malabsorption upper gastrointestinal tract active peptic ulcer Patients currently , resp . within last 30 day , participate study Primary focalsclerosing glomerulonephritis membranoproliferative glomerulonephritis underlie disease Autoimmune disease underlie disease ( collagen disease , colitis , HUS , SLE ) might require chronic cortisone therapy Additional disease require temporary chronic cortisone therapy ( include inhalation medicine ) Chronic hepatitis B hepatitis C infection Thrombopenia &lt; 70.000/mm3 leukopenia &lt; 2.500/mm3 neutropenia &lt; 1500/ mm3 . Patients hepatocirrhosis Child B C another severe disease liver Patients symptoms significant somatic psychiatric / mental illness . Patients able realize nature , relevance consequence clinical trial able comply , cooperate communicate adequately follow instruction study even give informed consent ( accord § 40 article 4 § 41 article 2 3 AMG ) . Patients possibly depend sponsor trial physician Patients sign drug abuse alcohol abuse Patients take additional medicine know interaction immune suppressive substance ( MMF tacrolimus ) preclude adequate control immunosuppression Cold ischemia time donor kidney &gt; 30 hour Pregnant nursing patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Kidney transplant status</keyword>
	<keyword>Steroid free</keyword>
	<keyword>Reduced</keyword>
	<keyword>Calcineurin</keyword>
	<keyword>Inhibitor</keyword>
	<keyword>Immunosuppression</keyword>
</DOC>